Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 16 to 90 years old
• People who have been diagnosed with brain glioma (a type of brain tumour) — including a first diagnosis, a return of the cancer, or cancer that has spread — confirmed through tissue testing
• People whose doctors estimate they have a life expectancy of more than 3 months
• People with a general health and physical ability score that meets a minimum level (known as Karnofsky ≥60% or ECOG 0–2 — confirm with trial site what this means for a specific situation)
• People whose cancer has not responded to standard treatments, or for whom no standard treatment options are available
• People who have a tumour area that doctors can safely biopsy or surgically remove, or who have fluid from the body where immune cells can be collected
• People who have at least one measurable tumour that can be tracked during the trial
• People whose recent blood test results (taken within 7 days before joining) show that blood cell counts, kidney function, liver function, and clotting levels all fall within the ranges required by the trial
• People who have no medical reason that would make surgery or a biopsy unsafe
• People of childbearing potential who are willing to use highly effective contraception from the time of signing the consent form through to one year after completing part of the treatment process
• People who have stopped any cancer-targeting treatments — including radiation, chemotherapy, or biological therapies — at least 28 days before the immune cell collection step
• People who are able to understand and sign the consent form
• People who are able to attend follow-up visits and meet the other requirements of the trial

Who may not be able to join:

• People who require steroid (glucocorticoid) treatment at a daily dose above the equivalent of 15mg of prednisone, or who have an autoimmune condition requiring immune-modifying treatment
• People with significantly reduced lung function, based on specific breathing test results (confirm details with trial site)
• People with serious heart conditions, including severe heart failure, very low blood pressure, uncontrolled coronary artery disease, poor heart pumping function, or significant abnormal heart rhythms or electrical conduction problems
• People who have HIV infection or test positive for HIV antibodies, have active hepatitis B or C infection, or have syphilis or a positive test for the bacteria that causes it
• People with severe physical or mental health conditions
• People who have an active infection throughout the body that requires treatment, or who have evidence of infection in blood tests or scans
• People who have received or are currently receiving other medicines, biological therapies, chemotherapy, or radiotherapy within the past month
• People with a known allergy to substances similar to those used in cell-based therapies
• People who previously received immunotherapy and experienced a serious immune-related side effect rated at level 3 or higher
• People who still have side effects from previous cancer treatments that have not reduced to a mild level (level 1 or below on a standard scale), except for certain effects like hair loss that doctors consider non-concerning
• People who are pregnant or breastfeeding
• People who have had an organ transplant, a stem cell transplant using donor cells, or kidney replacement therapy
• People whom the research team considers to have other serious medical conditions or circumstances that make participation in the trial inappropriate

Important: Always verify eligibility with the trial site directly before applying.